HOME >> BIOLOGY >> NEWS
Test method provides biocompatibility 'barometer'

A new method for quantitatively measuring the compatibility of materials with living tissues has been developed by researchers at the National Institute of Standards and Technology (NIST). Described in a Dec. 11 presentation at the Tissue Engineering Society International's conference in Orlando, Fla., the technique should provide a more sensitive and reliable means to evaluate the biocompatibility of new materials for a wide range of applications from contact lenses to dental coatings to bone implants.

A paper outlining the new method has been accepted for publication in the Journal of Biomedical Materials Research.

The new method, which represents a novel application of existing bench-top scientific instruments, is a two-step process. The first step involves using a device called a polymerase chain reaction instrument to measure the levels of an organism's cytokines when exposed to a given material. Cytokines are signaling molecules released by white blood cells to protect the body from foreign materials. Higher levels of cytokine production generally indicate non-biocompatible materials have caused inflammation. The second step involves testing exposed cells for a specific protein in the cell membrane, the presence of which indicates cells are dying. This is a complementary test for more serious responses to materials because dying cells are often not capable of producing cytokines. The NIST tests were conducted on cultured mouse cells, which produce similar responses as whole tissues.

NIST post-doctoral researcher LeeAnn Bailey called the new method a "barometer" of biocompatibility.

Whereas current means to test biocompatibility produce a yes/no result that a material is minimally biocompatible or not, the new analysis can tell which materials are more biocompatible than others. Industry and researchers should be able to use this method to produce new materials for dentistry and other medical applications that are even more well
'"/>

Contact: Scott Nance
scott.nance@nist.gov
301-975-5226
National Institute of Standards and Technology (NIST)
19-Dec-2003


Page: 1 2

Related biology news :

1. OHSU researchers discover possible method for early detection, prevention of premature birth
2. Japanese researchers develop novel method of introducing transgenes into animals
3. New screening method turns up potential compound for treating anthrax
4. Radiologists provide safe delivery method for gene therapy
5. New method is first to mimic subtle genetic changes
6. New method for determining age of artifacts fills chronological gap for scientists
7. Proven method of bone analysis may clarify human origins
8. UVa researchers describe method of protecting chromosomes during cell division
9. Computer method identifies potentially active enzymes
10. Risk and food are on the same plate: World food safety experts offer new methods to assess risk
11. Purdue engineers develop quick, inexpensive method to prototype microchips

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Test method provides biocompatibility barometer

(Date:3/20/2015)... 20, 2015 Research and Markets ... the "India Sensors Market Forecast and Opportunities ... The sensor market is projected to grow at ... Consumer electronics, automotive, industrial and healthcare sectors are ... country. In addition, adoption of MEMS technology in ...
(Date:3/20/2015)... Conn. , March 20, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... smart wallet is one of the products featured in ... March 20th at 11:00 PM EST on the DIY ... to Las Vegas , site of ...
(Date:3/19/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market, announces its biometric payment technology, the Wocket® smart ... week on Washington DC,s Fox 5 ... "The Next Great Thing", host Laura Evans calls ... ,a really big breakthrough in mobile payment.,  ...
Breaking Biology News(10 mins):India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3
(Date:4/16/2015)... MOSCOW , April 16, 2015 /PRNewswire/ ... (ChemRar), the Russian pharmaceutical investment and R&D ... announced collaboration for research, development and commercialization ... with the intention to stimulate ... industry.      (Logo: http://photos.prnewswire.com/prnh/20150416/739742-a) ,     ...
(Date:4/16/2015)... , April 16, 2015  AnaptysBio, Inc., a ... therapeutic antibodies, today announced the advancement of ... into IND-enabling studies. The Company,s anti-IL-36R therapeutic ... for generalized pustular psoriasis (GPP), an orphan ... need. ANB019 is wholly owned within AnaptysBio,s proprietary ...
(Date:4/16/2015)... , April 16, 2015 Avelas Biosciences, an ... improving cancer surgeries, announced today that it has initiated ... illuminator, AVB-620, in women with primary, non-recurrent breast cancer ... also welcomed the addition of Steven Chen , ... The open label, dose escalation study will enroll up ...
(Date:4/16/2015)... LAUSANNE , Switzerland ... Debiopharm International SA (Debiopharm), part of Debiopharm Group ™ ... prescription drugs that target unmet medical needs ... that preclinical data on the investigational compounds ... inhibitor) will be presented at the 2015 ...
Breaking Biology Technology:Lancet and ChemRar High Tech Center Have Announced a Partnership in the Development and Production of Novel Drugs in Russia 2AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 3
Cached News: